Allogene Therapeutics (ALLO) Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Do analysts recommend SPRY or ALLO?

ARS Pharmaceuticals presently has a consensus target price of $32.50, suggesting a potential upside of 239.60%. Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 647.30%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Allogene Therapeutics	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more volatility and risk, SPRY or ALLO?

ARS Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Which has higher valuation & earnings, SPRY or ALLO?

ARS Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$89.15M	10.61	$8M	-$0.49	-19.53
Allogene Therapeutics	$20K	12,536.22	-$257.59M	-$1.11	-1.02

Is SPRY or ALLO more profitable?

Allogene Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-42.74%	-21.85%	-15.88%
Allogene Therapeutics	N/A	-55.99%	-42.75%

Do insiders & institutionals have more ownership in SPRY or ALLO?

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor SPRY or ALLO?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for ARS Pharmaceuticals and 1 mentions for Allogene Therapeutics. ARS Pharmaceuticals' average media sentiment score of 1.11 beat Allogene Therapeutics' score of 0.87 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ARS Pharmaceuticals beats Allogene Therapeutics on 11 of the 17 factors compared between the two stocks.